SciClone Hit With Second Federal FCPA Securities Suit
The Hong Kong-based drugmaker said in an August regulatory filing that it was under investigation for potential Foreign Corrupt Practices Act violations.
To read more
Subscribe to Global Investigations Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Investigations Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10